Navigation Links
Third Pivotal Phase 3 Study for NicOx' Naproxcinod Shows Positive Efficacy, Safety and Blood Pressure Results
Date:11/24/2008

SOPHIA ANTIPOLIS, France, November 24 /PRNewswire-FirstCall/ -- NicOx S.A. (NYSE Euronext Paris: COX) today announced that the third pivotal phase 3 study for naproxcinod in patients with OA of the hip showed a highly statistically significant result (p<0.001) on all three co-primary efficacy endpoints of the trial. Naproxcinod 750 mg bid showed the same gastrointestinal (GI) adverse event rate and a similar blood pressure profile to placebo. Naproxcinod is the most advanced compound in a novel class of anti-inflammatory agents known as Cyclooxygenase-Inhibiting Nitric Oxide Donators (CINODs).

Following the positive results from the 301 and 302 studies in patients with OA of the knee, 303 represents the third phase 3 study for naproxcinod to achieve p<0.001 on all three co-primary efficacy endpoints. The 303 study is also the final pivotal trial that NicOx plans to include in the submission of a New Drug Application (NDA) to the US Food and Drug Administration (FDA) in mid-2009.

"This study has demonstrated clear-cut efficacy for naproxcinod 750 mg bid in hip OA, in addition to providing reassuring blood pressure and safety data," said Thomas J. Schnitzer, MD, PhD, Professor of Medicine at Northwestern University Feinberg School of Medicine, who advised NicOx on the design and analysis of the trial. "Meeting the primary endpoints of this study is a significant achievement, considering the difficultly in controlling the symptoms of hip OA patients. Few studies with other anti-inflammatory agents have focused only on people with hip OA, in part because of the increased difficulty in demonstrating efficacy in this population compared to knee OA. Additionally, the fact that the blood pressure data for naproxcinod and placebo were similar at all time points is also encouraging, as there is a definite need for new anti-inflammatory agents that do not increase blood pressure."

Result
'/>"/>

SOURCE NicOx
Copyright©2008 PR Newswire.
All rights reserved

13611

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Over $10 Million of CSL Behrings Privigen Was Sold in the U.S. During the Third Quarter of 2008
2. SCOLR Pharma, Inc. Reports Third Quarter 2008 Financial Results
3. Cadence Pharmaceuticals Reports Third Quarter 2008 Financial Results and Provides Clinical Development Programs Update
4. CuraGen to Host Conference Call and Webcast to Discuss Third Quarter 2008 Financial Results and CR011-vcMMAE Phase II Trial Results on November 3, 2008
5. Boston Scientific Completes Clinical Trial Enrollment for Third-Generation Drug-Eluting Stent
6. Physicians Estimate That if Approved, Ceftobiprole Will Steal Nearly a Third of Zyvoxs Patient Share in the Treatment of Nosocomial Pneumonia
7. NewCardio Announces Positive Results From Third Clinical Validation Study
8. Transcept Pharmaceuticals Announces Intent to Submit New Drug Application for Intermezzo(R) in Third Quarter 2008
9. NicOx Completes Patient Enrollment in Third Naproxcinod Pivotal Phase 3 Study
10. NeoStem Reports Positive Stem Cell Industry Research Trends From The Journal of the American Medical Association and Third Annual Stem Cell Summit
11. Tengion Launches Third Phase 2 Clinical Trial of Regenerated Human Bladder

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)...PRNewswire/ -- BioTrends Research Group, Inc. rele... report, the first in a multi-phase syndicated m...ocor Ortho-Biotech,s Stelara, from product launch ...h wave of the report provides quantitative informa... information from a subset of 20. The reports ass...
(Date:11/25/2009)...ov. 25 Remedium Technol...ike foam that stops severe bleeding, won first pri... category of the Global Security Challenge 2009, c...om more than 100 entries from around the world, Re...ecurity Summit conference held at the London Schoo...
(Date:11/25/2009)..., Nov. 25 /PRNewswire-Asia-FirstCall/ -- China Sky...e Company") (Nasdaq: CSKI ), a,leading fully inte...cing,over-the-counter drugs in the People,s Republ...any recently passed the Chinese National Institute...Products ("ICPBP") examination,for two of its new ...
Breaking Medicine Technology:Despite Managed Care Obstacles, Interest and Anticipated Use of Centocor Ortho-Biotech's New Psoriasis Agent Stelara (ustekinumab) is High 2Remedium Technologies Wins Most Promising Security Idea at Global Security Challenge 2009 with Blood-Clotting Foam 2Remedium Technologies Wins Most Promising Security Idea at Global Security Challenge 2009 with Blood-Clotting Foam 3China Sky One Medical, Inc. Achieved Progress in the Development of Two New Biological Testing Kits 2China Sky One Medical, Inc. Achieved Progress in the Development of Two New Biological Testing Kits 3Sharp HealthCare and Anakam 28R 29 Partner to Protect Patients Health Information 49971 1Sharp HealthCare and Anakam 28R 29 Partner to Protect Patients Health Information 49971 2Sharp HealthCare and Anakam 28R 29 Partner to Protect Patients Health Information 49971 3Nations Staff RNs Call on Congress to Implement Public Health Care Option 49966 1Nations Staff RNs Call on Congress to Implement Public Health Care Option 49966 2Kewaunee Scientific Reports Record Results Net Earnings for Year Increase 36 25 Sales Increase 16 25 12772 1Kewaunee Scientific Reports Record Results Net Earnings for Year Increase 36 25 Sales Increase 16 25 12772 2Kewaunee Scientific Reports Record Results Net Earnings for Year Increase 36 25 Sales Increase 16 25 12772 3Kewaunee Scientific Reports Record Results Net Earnings for Year Increase 36 25 Sales Increase 16 25 12772 4Kewaunee Scientific Reports Record Results Net Earnings for Year Increase 36 25 Sales Increase 16 25 12772 5
..., ATLANTA, April 9, 2008 Dutch biotechnology,co...undation and the South,African Tuberculosis Vaccin... immunology data from a Phase I Ad35 tuberculosis ...es for the World" conference (Atlanta,Georgia, Apr...er, South,Africa and launched in May 2007, is the ...
...Selective Kinase Inhibitor Phase 1 Trial in Advanc... EntreMed, Inc.,(Nasdaq: ENMD ), a clinical-stag...or the treatment of cancer and inflammatory diseas...1, dose-escalation study for its,selective kinase ... Dr.,Wells Messersmith, University of Colorado Can...
Other Medicine Technology:Aeras, Crucell and South African Tuberculosis Vaccine Initiative Announce Encouraging Preliminary Results of Tuberculosis Vaccine Clinical Trial in South Africa 2Aeras, Crucell and South African Tuberculosis Vaccine Initiative Announce Encouraging Preliminary Results of Tuberculosis Vaccine Clinical Trial in South Africa 3Aeras, Crucell and South African Tuberculosis Vaccine Initiative Announce Encouraging Preliminary Results of Tuberculosis Vaccine Clinical Trial in South Africa 4Aeras, Crucell and South African Tuberculosis Vaccine Initiative Announce Encouraging Preliminary Results of Tuberculosis Vaccine Clinical Trial in South Africa 5Aeras, Crucell and South African Tuberculosis Vaccine Initiative Announce Encouraging Preliminary Results of Tuberculosis Vaccine Clinical Trial in South Africa 6EntreMed Achieves a Key Milestone Through Initiation of ENMD-2076 Clinical Program 2EntreMed Achieves a Key Milestone Through Initiation of ENMD-2076 Clinical Program 3EntreMed Achieves a Key Milestone Through Initiation of ENMD-2076 Clinical Program 4
(Date:11/27/2009)..., Mass., Nov. 27 GSI Gro...plier of precision technology products and semicon...ting of the Company,s shareholders has been schedu...tion of the meeting will be announced in due cours...a requisition notice from Stephen Bershad, a holde...
(Date:11/27/2009)...R, N.Y., Nov. 27 Preven...ider and fortunately every year, new vaccines are ...o all vaccines boost immunity for the same period ... shots, needed to keep immunity strong? ,, In...the American Academy of Pediatrics, Michael Pichic...
(Date:11/27/2009)...ng unprecedented medical, economic burdens, study ...News) -- The number of people with diabetes in the... 25 years, a new study predicts. , That would b...e with the disease, up from 23.7 million today. ,...with diabetes will triple, the study also warns, r...
(Date:11/27/2009)... Three new interactive anatomy education apps...ns expand health sciences learning opportunities f... Durham, NC (Vocus) November 27, 2009 -- Modalit...W), a division of Wolters Kluwer Health, today ann...tion apps on the App Store. Clemente’s Anato...
(Date:11/26/2009)...ig or too heavy can lead to strains or worse , ...re may be nothing wrong with stuffing your turkey ... same thing with your suitcase as you pack for hol...ted in 2008 in U.S. hospital emergency rooms, doct... for luggage-related injuries, such as muscle stra...
Breaking Medicine News(10 mins):Health News:GSI Group Calls Shareholders Meeting 2Health News:Why Some Vaccines May Require A Booster 2Health News:Why Some Vaccines May Require A Booster 3Health News:Diabetes Cases Expected to Double in 25 Years 2Health News:Diabetes Cases Expected to Double in 25 Years 3Health News:Clemente's Anatomy, Rohen's Photographic Anatomy, and Moore's Clinical Anatomy Customizable Apps Now Available on App Store 2Health News:Clemente's Anatomy, Rohen's Photographic Anatomy, and Moore's Clinical Anatomy Customizable Apps Now Available on App Store 3Health News:Clemente's Anatomy, Rohen's Photographic Anatomy, and Moore's Clinical Anatomy Customizable Apps Now Available on App Store 4Health News:Clemente's Anatomy, Rohen's Photographic Anatomy, and Moore's Clinical Anatomy Customizable Apps Now Available on App Store 5Health News:Pack Right for the Holidays to Avoid the ER 2
...er characterized by severe impairment in the abili... Most people who have the // condition are diagno...elop normal social and communication skills. Se...tetric complications. Researchers studied the med...
...pilepsy may be risking bone loss say researchers. ...nd // those on epilepsy drugs were significantly m...sts to measure bone density than women not taking ...d the hip. Those numbers held true even after the ...
...yndrome cases were 10 per 100,000 women, but dropp... tampons were // taken off the market. The number ...t toxic shock syndrome statistics at 5 per 100,000...ymptoms include fever, rashes, vomiting, diarrhea,...
...hat there might be a relationship between the stat...quality of life during cancer treatment.// For...n nearly 500 patients who had metastatic colorecta... that involves common side effects, such as fatigu...
...ar-sweetened soft drinks may increase a woman’s ri...udy researchers followed women between ages 26 and...ne of the participants had diabetes or any other s...han those who drank less than one soda a day. W...
...em with patients effected with cancer. It is repor... risk of sleeplessness as compared to healthy peop...t sleep. No matter how many sheep fly over that be...stern University in Chicago, says sleeplessness in...
Other Medicine News:
Mayo scissors
Straight scissors
Reddick/Saye Needle Holder, Straight
MultAcoice™ Biopsy Forceps
Medicine Products: